Description
The human p65 (RELA) protein is a subunit of the transcription factor NF-κB [Reference]. The “dCas9-p65” fusion can be used in regulation of NF-kB pathway. Under the guidance of gRNA, dCas9 transport the p65 to the targeted locus where to activate the transcription of specific target genes in a controlled manner [Reference] . The “dCas9-P65” fusion creates a CRISPR based, highly potent transcriptional activator ( CRISPRa ), for the targeted genes.
This premade lentivirus express the dCa9-P65 fusion under the enhanced CMV promoter (SuCMV), carrying Neomycin (G418) selection. It can be used to activate the desired genes, or generate a genome-wide activation-ready cell line, which can then be used for the targeted gene-expression activation upon gRNA addition for screening and profiling assay.
If desired, the negative control lentivirus, CAT#: LVP1596, which has the dCas9 fusioned with a Null sequence, can be used as the non-specific, background control.
To up-regulate your desired gene, simply apply this lentivirus to your cells and then add the targeting gRNA lentivirus (which need to be designed and made separately according to your target locus.), or apply this lentivirus together with your desired gRNA lentivirus. (Note: Contact us if you need to make your desired gRNA lentivirus via a customized order).
see details in Product Manual.
Amount: 200 ul/vial, at titer of 1×108 IFU/ml, provided in PBS solution (premixed with 10x polybrene, 60 ug/ml).
CAT#: LVP1576
